Mesoblast raises $260 million for Ryoncil's US launch and further developments.
Posted on: 13/01/2025
Mesoblast Limited requests trading halt pending financing announcement.
Posted on: 09/01/2025
Mesoblast Limited pauses trading pending further announcement.
Melbourne firm releases significant ASX announcement after trading pause.
Posted on: 05/12/2024
Posted on: 04/12/2024
FDA grants RMAT designation to Mesoblast's Revascor for congenital heart disease treatment.
Mesoblast provides updates on FDA reviews and financial performance for Q4 2024.
Posted on: 30/07/2024
FDA accepts Mesoblast's BLA for Ryoncil in treating pediatric SR-aGVHD.
Posted on: 23/07/2024
Mesoblast resubmits BLA for Ryoncil to treat children with SR-aGVHD.
Posted on: 08/07/2024